Objective: To explore the role of IGF signal axis in promoting cell proliferation and anti-apoptosis of CD117+ CD44+ A2780, the ovarian cancer stem cell-like cells, discussing the targeting therapy based on IGF signal axis of IGF-1R and looking for possible ways to reduce the recurrence of ovarian cancer after chemotherapy. Materials and Methods: This experiment used CD117+ CD44+ A2780 ovarian cancer cell line, the expression of IGF-1, IGF-2 and IGF-1R of IGF signal axis in CD117+ CD44+ A2780 were detected by immune histochemical method; cells proliferation which was promoted by IGF-1 was measured by MTT assay in CD117+ CD44+ A2780, the concentration of IGF-1 was respectively 10, 25, 40, 55 ng·ml-1 and blank group. The suitable concentration of IGF-1 was selected and used in subsequent experiment; then the experiment was divided into three group: IGF-1 stimulate group, NVP inhibit group and blank group, the cell cycle and apoptosis rate were analyzed by flow cytometry after 48 h drug treatment. Results: IGF-1, IGF-2 and IGF-1R of IGF signal axis expressed in CD117+ CD44+ A2780's cell membrane and cytoplasm; MTT test experimented on CD117+ CD44+ A2780 selected the suitable concentration of the four group of exogenous IGF-1, with a concentration of 40 ng·ml-1 obviously promoting the proliferation; flow cytometry showed more active proliferation and a decreased apoptosis rate in IGF-1 stimulating group compared with the blank group(P<0.05); NVP inhibiting group, compared with blank group, inhibited proliferation and increased apoptosis rate(P<0.05). Conclusion: IGF signal axis has close relationship with the recurrence of ovarian cancer after chemotherapy; IGF-1 plays an important role in transforming the state of proliferation and anti-apoptosis; NVP can block the effect of IGF-1, stop ovarian cancer stem cell-like cells transforming from quiescent state to growth state; IGF axis can be used as target proteins in ovarian cancer treatment and prevention of recurrence after chemotherapy. |
[1] BAST R C,Jr MARKMAN M.Chemotherapy:a new standard combination for recurrent ovarian cancer?[J].Nat Rev Clin Oncol,2010,7(10):559-560.
[2] BURGOS-OJEDA D,RUEDA B,RBUCKANOVICH R J.Ovarian cancer stem cell markers:prognostic and therapeutic implications[J].Cancer Lett,2012,322(1):1-7.
[3] BEAUCHAMP M C,YASMEEN A,KNAFO A,et al.Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer[J].J Oncol,2010,2010:257058.
[4] JIN M,BUCK EMULVIHILL M J.Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer:current status and future perspectives[J].Oncol Rev,2013,7(1):e3.
[5] BROKAW J,KATSAROS D A,LU L,et al.IGF-I in epithelial ovarian cancer and its role in disease progression[J].Growth Factors,2007,25(5):346-354.
[6] DOUGLAS J B,SILVERMAN D T,POLLAK M N,et al.Serum IGF-I,IGF-II,IGFBP-3,and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate,lung,colorectal,and ovarian cancer screening trial[J].Cancer Epidemiol Biomarkers Prev,2010,19(9):2298-2306.
[7] KURODA Y,KATO-KOGOE N,TASAKI E,et al.Suppressive effect of membrane-permeable peptides derived from autophosphorylation sites of the IGF-1 receptor on breast cancer cells[J].Eur J Pharmacol,2015,765:24-33.
[8] SLOMIANY M G,BLACK L A,KIBBEY M M,et al.Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma[J].Cancer Lett,2007,248(2):269-279.
[9] SHUKLA S,GUPTA S.Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer:an in vitro and in vivo study[J].Mol Carcinog,2009,48(3):243-252.
[10] TOMIZAWA M.Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer[J].World J Gastroenterol,2010,16(15):1854.
[11] VANAMALA J,REDDIVARI L,RADHAKRISHNAN S,et al.Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways[J].BMC Cancer,2010,10:238.
[12] SMITH T J.Insulin-like growth factor-I regulation of immune function:a potential therapeutic target in autoimmune diseases?[J].Pharmacol Rev,2010,62(2):199-236.
[13] GALLAGHER E J,LEROITH D.The proliferating role of insulin and insulin-like growth factors in cancer[J].Trends Endocrinol Metab,2010,21(10):610-618.
[14] FLEUREN E D,VERSLEIJEN-JONKERS Y M,van de LUIJTGAARDEN A C,et al.Predicting IGF-1R therapy response in bone sarcomas:immuno-SPECT imaging with radiolabeled R1507[J].Clin Cancer Res,2011,17(24):7693-7703.
[15] FARHANA L,DAWSON M I,DAS J K,et al.Adamantyl retinoid-related molecules induce apoptosis in pancreatic cancer cells by inhibiting IGF-1R and Wnt/beta-catenin pathways[J].J Oncol,2012,2012:796729. |